And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda — or at least the items we can remember — our rather modest. We plan to catch up on some reading, take several naps, and stroll about town. And what about you? This is a lovely time of year to enjoy the great outdoors. You could pick a few apples or, if you feel brave, search for The Great Pumpkin. You could make time for someone special or, if you prefer, research your health plan for next year. For the mischievous among you, perhaps wager a bet on which country that certain someone in the White House will next ask for help in probing political rivals. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon.

When Congress passed a drug pricing bill last week that will save the government $3 billion — the first such bill passed in nearly a year — no one really noticed, STAT notices. There was no press conference from the bill sponsors, no snarky reaction from the drug industry, virtually no press release from any of the advocacy organizations that champ at the bit to weigh in on every twist and turn of the ongoing drug pricing debate in Washington. But the bill would change the way discounts are calculated for authorized generics in the Medicaid program.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy